首页> 外文期刊>The oncologist >Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial
【24h】

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial

机译:舒尼替尼治疗晚期非透明细胞肾细胞癌晚期患者的高血压,循环细胞因子和血管生成因子:II期试验结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background. We evaluated the significance of hypertension developing during vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (VEGFR-TKI) treatment and a group of cytokines and angiogenic factors (CAFs) in advanced non-clear cell renal cell carcinoma (nccRCC) patients treated with sunitinib in a phase II study.
机译:背景。我们评估了在治疗的晚期非透明细胞肾细胞癌(nccRCC)患者中血管内皮生长因子(VEGF)受体酪氨酸激酶抑制剂(VEGFR-TKI)和一组细胞因子和血管生成因子(CAF)期间高血压发展的重要性在舒尼替尼的II期研究中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号